Gene therapy CDMOs play critical role in enabling AAV process improvement & standardization - Ascend

Ascend is a gene-to-GMP development partner specializing in advanced therapy manufacturing with 60+ years of custom biologics and vaccines expertise and 20+ years of AAV development experience. The company supports gene therapies, immunotherapies, oncolytics, and vaccines across development and manufacturing scales.

Core Capabilities:

• AAV vector development and manufacturing with focus on process improvement and standardization
• Gene therapy manufacturing and process development
• Fill-finish capabilities in multiple US locations
• Next-generation technologies and analytics
• Deep regulatory expertise for advanced therapy products

Service Philosophy: Ascend emphasizes higher yields of AAV, higher purity of fully loaded vectors, higher sensitivity of assays, and higher proportion of milestones met. The company positions itself as a collaborative partner supporting life-science innovators from bench through clinic and beyond.